Dose Finding Study of GH35 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-12
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of GH35 in patients with KRAS mutant advanced solid
tumors.
Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in
patients with KRAS mutant advanced solid tumors.